Top

Journal of Nuclear Cardiology

Published in:

01-10-2015 | Review Article

Impact of medications on mIBG uptake, with specific attention to the heart: Comprehensive review of the literature

Authors: Arnold F. Jacobson, MD, PhD, Mark I. Travin, MD

Published in: Journal of Nuclear Cardiology | Issue 5/2015

Abstract

Background

A critical review of the literature on drug interactions with mIBG uptake was performed to allow formulation of contemporary guidance regarding withholding medications prior to clinical imaging studies.

Methods

Published information was extracted on the experimental system used, the quantitative characteristics of the measurements, and whether any data directly examining cardiac tissues were included. Level of evidence for each medication category was assessed on a qualitative scale of very low, low, medium, or high. Strength of medication effect for inhibition of mIBG uptake was judged as none, weak, moderate, or strong.

Results

The only medications for which level of evidence was judged high were labetalol and reserpine. Level of evidence was judged medium for tricyclic antidepressants, calcium channel blockers, and antiarrhythmics (specifically amiodarone). Evidence was judged sufficient to recommend withholding labetalol and the tricyclic antidepressants prior to mIBG cardiac imaging. Mechanistic evidence was sufficient to suggest consideration of withdrawal of sympathomimetic amines and serotonin-norepinephrine reuptake inhibitors (SNRIs).

Conclusions

As there is strong evidence for inhibition of mIBG uptake in only a small number of compounds, clinical decisions regarding withdrawal of concomitant medications should be individualized by considering the potential consequences of a false-positive (artificially low cardiac uptake) imaging result.

Wieland DM, Swanson DP, Brown LE, Beierwaltes WH. Imaging the adrenal medulla with an I-131-labeled antiadrenergic agent. J Nucl Med. 1979;20:155-8.PubMed

Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergic neuron-blocking agents: Adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med. 1980;21:349-53.PubMed

Sisson JC, Wieland DM. Radiolabelled meta-iodobenzylguanidine: Pharmacology and clinical studies. Am J Physiol Imaging. 1986;1:96-103.PubMed

Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH. Radioiodinated metaiodobenzylguanidine: A review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med. 1994;21:545-59.PubMedCrossRef

Solanki K, Bomanji J, Moyes J, Mather S, et al. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun. 1992;13:513-21.PubMedCrossRef

Bombardieri E, Giammarile F, Aktolun C, et al. (131)I/ (123)I-Metaiodobenzylguanidine (mIBG) scintigraphy: Procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:2436-46.PubMedCrossRef

Travin M. Cardiac radionuclide imaging to assess patients with heart failure. Semin Nucl Med. 2014;44:294-313.PubMedCrossRef

Stefanelli A, Treglia G, Bruno I, Rufini V, Giordano A. Pharmacological interference with 123I-metaiodobenzylguanidine: A limitation to developing cardiac innervation imaging in clinical practice? Eur Rev Med Pharmacol Sci. 2013;17:1326-33.PubMed

Blake GM, Lewington VJ, Fleming JS, Zivanovic MA, Ackery DM. Modification by nifedipine of 131I-meta-iodobenzylguanidine kinetics in malignant phaeochromocytoma. Eur J Nucl Med. 1988;14:345-8.PubMed

10.

Estorch M, Carrio I, Mena E, Flotats A, et al. Challenging the neuronal MIBG uptake by pharmacological intervention: Effect of a single dose of oral amitriptyline on regional cardiac MIBG uptake. Eur J Nucl Med Mol Imaging. 2004;31:1575-80.PubMedCrossRef

11.

Gulati V, Ching G, Heller GV. The role of radionuclide imaging in heart failure. J Nucl Cardiol. 2013;20:1173-83.PubMedCrossRef

12.

Jain KK, Hauptman PJ, Spertus JA, et al. Incremental utility of iodine-123 meta-iodobenzylguanidine imaging beyond established heart failure risk models. J Card Failure. 2014;20:577-83.CrossRef

13.

Suwa M, Otake Y, Moriguchi A, et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. Am Heart J. 1997;133:353-8.PubMedCrossRef

14.

Yamazaki J, Muto H, Kabano T, Yamashina S, Nanjo S, Inoue A. Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy—clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography. Am Heart J. 2001;141:645-52.PubMedCrossRef

15.

Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2003;41:574-81.PubMedCrossRef

16.

Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med. 2003;44:884-90.PubMed

17.

Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Effects of perindopril on cardiac sympathetic nerve activity in patients with congestive heart failure: Comparison with enalapril. Eur J Nucl Med Mol Imaging. 2005;32:964-71.PubMedCrossRef

18.

Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol. 2005;45:661-7.PubMedCrossRef

19.

Treglia G, Stefanelli A, Bruno I, Giordano A. Clinical usefulness of myocardial innervation imaging using Iodine-123-meta-iodobenzylguanidine scintigraphy in evaluating the effectiveness of pharmacological treatments in patients with heart failure: An overview. Eur Rev Med Pharmacol Sci. 2013;17:56-68.PubMed

20.

Apeldoorn L, Voerman HJ, Hoefnagel CA. Interference of MIBG uptake by medication: A case report. Neth J Med. 1995;46:239-43.PubMedCrossRef

21.

Babich JW, Graham W, Fischman AJ. Effect of adrenergic receptor ligands on metaiodobenzylguanidine uptake and storage in neuroblastoma cells. Eur J Nucl Med. 1997;24:538-43.PubMed

22.

Blake GM, Lewington VJ, Zivanovic MA, Ackery DM. Glomerular filtration rate and the kinetics of 123I-metaiodobenzylguanidine. Eur J Nucl Med. 1989;15:618-23.PubMed

23.

Cornelissen J, Tytgat GA, Van den Brug M, et al. Menadione inhibits MIBG uptake in two neuroendocrine cell lines. J Neurooncol. 1997;31:147-51.PubMedCrossRef

24.

Degrado TR, Zalutsky MR, Vaidyanathan G. Uptake mechanisms of meta-123I-iodobenzylguanidine in isolated rat heart. Nucl Med Biol. 1995;22:1-12.PubMedCrossRef

25.

Fagret D, Wolf JE, Comet M. Myocardial uptake of meta-[123I]-iodobenzylguanidine [(123I]-MIBG) in patients with myocardial infarct. Eur J Nucl Med. 1989;15:624-8.PubMedCrossRef

26.

Fagret D, Wolf JE, Vanzetto G, Borrel E. Myocardial uptake of metaiodobenzylguanidine in patients with left ventricular hypertrophy secondary to valvular aortic stenosis. J Nucl Med. 1993;34:57-60.PubMed

27.

Gasnier B, Roisin MP, Scherman D, Coornaert S, Desplanches G, Henry JP. Uptake of meta-iodobenzylguanidine by bovine chromaffin granule membranes. Mol Pharmacol. 1986;29:275-80.PubMed

28.

Gross MD, Shapiro B, Sisson JC, Zweifler A. Clonidine-induced suppression of plasma catecholamines in states of adrenal medulla hyperfunction. J Endocrinol Investig. 1987;10:359-64.CrossRef

29.

Guilloteau D, Baulieu JL, Huguet F, et al. Meta-iodobenzylguanidine adrenal medulla localization: autoradiographic and pharmacologic studies. Eur J Nucl Med. 1984;9:278-81.PubMedCrossRef

30.

Guilloteau D, Chalon S, Baulieu JL, et al. Comparison of MIBG and monoamines uptake mechanisms: pharmacological animal and blood platelets studies. Eur J Nucl Med. 1988;14:341-4.PubMed

31.

Harada K, Nomura M, Nishikado A, Uehara K, Nakaya Y, Ito S. Clinical efficacy of efonidipine hydrochloride, a T-type calcium channel inhibitor, on sympathetic activities. Circ J. 2003;67:139-45.PubMedCrossRef

32.

Hoefnagel CA, Schornagel J, Valdes Olmos RA. [131I]metaiodobenzylguanidine therapy of malignant pheochromocytoma: Interference of medication. J Nucl Biol Med. 1991;35:308-12.PubMed

33.

Huguet F, Fagret D, Caillet M, Piriou A, Besnard JC, Guilloteau D. Interaction of metaiodobenzylguanidine with cardioactive drugs: An in vitro study. Eur J Nucl Med. 1996;23:546-9.PubMedCrossRef

34.

Ito K, Sugihara H, Nishikawa S, et al. [Clinical usefulness of a dual L/N-type Ca²⁺ channel blocker, cilnidipine, in patients with chronic heart failure: assessment with 123I-MIBG myocardial scintigraphy]. Kaku Igaku. 2003;40:421-30.PubMed

35.

Jaques S Jr, Tobes MC, Sisson JC. Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: Evidence for uptake-one. Cancer Res. 1987;47:3920-8.PubMed

36.

Jaques S Jr, Tobes MC, Sisson JC, Baker JA, Wieland DM. Comparison of the sodium dependency of uptake of meta-lodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol Pharmacol. 1984;26:539-46.PubMed

37.

Khafagi FA, Shapiro B, Fig LM, Mallette S, Sisson JC. Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med. 1989;30:481-9.PubMed

38.

Ko BH, Paik JY, Jung KH, et al. Effects of anesthetic agents on cellular (123)I-MIBG transport and in vivo (123)I-MIBG biodistribution. Eur J Nucl Med Mol Imaging. 2008;35:554-61.PubMedCrossRef

39.

Kosaka T, Nakagawa M, Ishida M, et al. Cardioprotective effect of an L/N-type calcium channel blocker in patients with hypertensive heart disease. J Cardiol. 2009;54:262-72.PubMedCrossRef

40.

Lashford LS, Hancock JP, Kemshead JT. Meta-iodobenzylguanidine (mIBG) uptake and storage in the human neuroblastoma cell line SK-N-BE(2C). Int J Cancer. 1991;47:105-9.PubMedCrossRef

41.

Lee KH, Ko BH, Paik JY, et al. Characteristics and regulation of 123I-MIBG transport in cultured pulmonary endothelial cells. J Nucl Med. 2006;47:437-42.PubMed

42.

Mairs RJ, Gaze MN, Barrett A. The uptake and retention of metaiodobenzyl guanidine by the neuroblastoma cell line NB1-G. Br J Cancer. 1991;64:293-5.PubMedCentralPubMedCrossRef

43.

Mayer S, Karanikas G, Rodrigues M, Sinzinger H. Influence of drugs on myocardial iodine-123 metaiodobenzylguanidine uptake in rabbit myocardium. Eur J Nucl Med. 2000;27:340-5.PubMedCrossRef

44.

Morais J, Le Marec H, Peltier P, et al. MIBG scintigraphy of a patient with pheochromocytoma on labetalol therapy. Clin Nucl Med. 1992;17:308-11.PubMedCrossRef

45.

Muraoka T, Oku E, Sugataka K, Yamada S. A case of severe parkinsonism associated with short-term treatment with milnacipran. Clin Neuropharmacol. 2008;31:299-300.PubMedCrossRef

46.

Nakajo M, Shapiro B, Sisson JC, Swanson DP, Beierwaltes WH. Salivary gland accumulation of meta-131I-iodobenzylguanidine. J Nucl Med. 1984;25:2-6.PubMed

47.

Nori S, Calcagn ML, Martire M, et al. Scintigraphic imaging of neuroadrenergic cardiac function: An in vitro and in-vivo study. Biomed Res. 2003;14:11-6.

48.

Rutgers M, Tytgat GA, Verwijs-Janssen M, Buitenhuis C, Voute PA, Smets LA. Uptake of the neuron-blocking agent meta-iodobenzylguanidine and serotonin by human platelets and neuro-adrenergic tumour cells. Int J Cancer. 1993;54:290-5.PubMedCrossRef

49.

Sakaki T, Naruse H, Masai M, et al. Cilnidipine as an agent to lower blood pressure without sympathetic nervous activation as demonstrated by iodine-123 metaiodobenzylguanidine imaging in rat hearts. Ann Nucl Med. 2003;17:321-6.PubMedCrossRef

50.

Sakata K, Shirotani M, Yoshida H, Kurata C. Comparison of effects of enalapril and nitrendipine on cardiac sympathetic nervous system in essential hypertension. J Am Coll Cardiol. 1998;32:438-43.PubMedCrossRef

51.

Sakata K, Shirotani M, Yoshida H, et al. Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Hypertension. 1999;33:1447-52.PubMedCrossRef

52.

Sakata K, Yoshida H, Tamekiyo H, et al. Comparative effect of clinidipine and quinapril on left ventricular mass in mild essential hypertension. Drugs Exp Clin Res. 2003;29:117-23.PubMed

53.

Sawka AM, Young WF, Schaff HV. Cardiac phaeochromocytoma presenting with severe hypertension and chest pain. Clin Endocrinol (Oxf). 2001;54:689-92.CrossRef

54.

Schwebel C, Fagret D, Tremel F, et al. Action of labetalol on norepinephrine myocardial content in left ventricular hypertrophy in hypertensive patients. Arch Mal Coeur Vaiss. 1992;85:1103-6.PubMed

55.

Sisson JC, Frager MS, Valk TW, et al. Scintigraphic localization of pheochromocytoma. New Engl J Med. 1981;305:12-7.PubMedCrossRef

56.

Sisson JC, Shapiro B, Meyers L, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med. 1987;28:1625-36.PubMed

57.

Sisson JC, Wieland DM, Jaques S Jr, et al. Radiolabeled meta-iodobenzylguanidine and the adrenergic neurons of salivary glands. Am J Physiol Imaging. 1987;2:1-9.PubMed

58.

Sisson JC, Wieland DM, Sherman P, Mangner TJ, Tobes MC, Jacques S Jr. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med. 1987;28:1620-4.PubMed

59.

Smets LA, Janssen M, Metwally E, Loesberg C. Extragranular storage of the neuron blocking agent meta-iodobenzylguanidine (MIBG) in human neuroblastoma cells. Biochem Pharmacol. 1990;39:1959-64.PubMedCrossRef

60.

Tachikawa H, Kodama M, Watanabe K, et al. Amiodarone improves cardiac sympathetic nerve function to hold norepinephrine in the heart, prevents left ventricular remodeling, and improves cardiac function in rat dilated cardiomyopathy. Circulation. 2005;111:894-9.PubMedCrossRef

61.

Tobes MC, Jaques S Jr, Wieland DM, Sisson JC. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med. 1985;26:897-907.PubMed

62.

Toyama T, Hoshizaki H, Seki R, et al. Efficacy of amiodarone treatment on cardiac symptom, function, and sympathetic nerve activity in patients with dilated cardiomyopathy: Comparison with [beta]-blocker therapy. J Nucl Cardiol. 2004;11:134-41.PubMedCrossRef

63.

Toyama T, Hoshizaki H, Yoshimura Y, et al. Combined therapy with carvedilol and amiodarone is more effective in improving cardiac symptoms, function, and sympathetic nerve activity in patients with dilated cardiomyopathy: Comparison with carvedilol therapy alone. J Nucl Cardiol. 2008;15:57-64.PubMedCrossRef

64.

Wakabayashi Y, Kurata C, Mikami T, Shouda S, Okayama K, Tawarahara K. Effects of cilazapril and verapamil on myocardial iodine-125-metaiodobenzylguanidine accumulation in cardiomyopathic BIO 53.58 hamsters. J Nucl Med. 1997;38:1540-5.PubMed

65.

Wieland DM, Brown LE, Rogers WL, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med. 1981;22:22-31.PubMed

66.

Wieland DM, Brown LE, Tobes MC, et al. Imaging the primate adrenal medulla with [123I] and [131I] meta-iodobenzylguanidine: Concise communication. J Nucl Med. 1981;22:358-64.PubMed

67.

Yokoyama K, Yamada T, Terachi S, et al. Milnacipran influences the indexes of I-metaiodobenzylguanidine scintigraphy in elderly depressed patients. Psychiatr Clin Neurosci. 2014;68:169-75.CrossRef

68.

Zaplatnikov K, Menzel C, Dobert N, et al. Case report: Drug interference with MIBG uptake in a patient with metastatic paraganglioma. Br J Radiol. 2004;77:525-7.PubMedCrossRef

69.

Nomura Y, Matsunari I, Takamatsu H, et al. Quantitation of cardiac sympathetic innervation in rabbits using 11C-hydroxyephedrine PET: Relation to 123I-MIBG uptake. Eur J Nucl Med Mol Imaging. 2006;33:871-8.PubMedCrossRef

70.

Rischpler C, Fukushima K, Isoda T, et al. Discrepant uptake of the radiolabeled norepinephrine analogues hydroxyephedrine (HED) and metaiodobenzylguanidine (MIBG) in rat hearts. Eur J Nucl Med Molec Imaging. 2013;40:1077-83.CrossRef

71.

Shapiro B, Wieland D, Brown L, et al. I-131-metaiodobenzylguanidine (MIBG) adrenal medullary scintigraphy. Interventional studies. In: Spencer RD, editor. Interventional nuclear medicine. Grune and Stratton: Orlando; 1984. p. 451-81.

72.

Corbett RP, Peacock J, Meller ST. Inhibition of 125I metaiodobenzylguanidine (mIBG) uptake into neuroblastoma monolayers by antiemetic agents (abstr). Eur J Nucl Med. 1991;18:678.

73.

Jaques S, Tobes MC, Sisson JC, et al. Effect of calcium channel blockers on acetylcholine stimulated and basal release of metaiodobenzylguanidine and norepinephrine in cultured bovine adrenomedullary cells (abstr). J Nucl Med. 1987;28:639-40.

74.

Sherman PS, Fisher SJ, Wieland DM, Sisson JC. Over the counter drugs block heart accumulation of MIBG (abstr). J Nucl Med. 1985;26:P35.

75.

Doggrell SA, Patton DM. Effect of labetalol on the accumulation and release of noradrenaline in rat ventricle. Eur J Pharmacol. 1978;51:303-7.PubMedCrossRef

76.

Role LW, Perlman RL. Catecholamine uptake into isolated adrenal chromaffin cells: Inhibition of uptake by acetylcholine. Neuroscience. 1983;10:987-96.PubMedCrossRef

77.

Daly JW, Creveling CR, Witkop B. The chemorelease of norepinephrine from mouse hearts. Structure-activity relationships. I. Sympathomimetic and related amines. J Med Chem. 1966;9:273-80.PubMedCrossRef

78.

Daly JW, Creveling CR, Witkop B. The chemorelease of norepinephrine in mouse hearts. Structure-activity relationships. II. Drugs affecting the sympathetic and central nervous systems. J Med Chem. 1966;9:280-4.PubMedCrossRef

79.

Starke K. Influences of phenylephrine and orciprenaline on the release of noradrenaline. Experientia. 1973;29:579-80.PubMedCrossRef

80.

Malizia AL, Melichar JK, Rhodes CG, et al. Desipramine binding to noradrenaline reuptake sites in cardiac sympathetic neurons in man in vivo. Eur J Pharmacol. 2000;391:263-7.PubMedCrossRef

81.

DeGrado TR, Hutchins GD, Toorongian SA, Wieland DM, Schwaiger M. Myocardial kinetics of carbon-11-meta-hydroxyephedrine: Retention mechanisms and effects of norepinephrine. J Nucl Med. 1993;34:1287-93.PubMed

82.

Sekine M, Arakawa R, Ito H, et al. Norepinephrine transporter occupancy by antidepressant in human brain using positron emission tomography with (S, S)-[18F]FMeNER-D2. Psychopharmacology. 2010;210:331-6.PubMedCrossRef

83.

Takano A, Nag S, Gulyas B, Halldin C, Farde L. NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo. Psychopharmacology (Berl). 2011;216:279-86.CrossRef

84.

Nogami T, Takano H, Arakawa R, et al. Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: A positron emission tomography study with [11C]DASB and (S, S)-[18F]FMeNER-D2. Int J Neuropsychopharmacol. 2013;16:937-43.PubMedCrossRef

85.

Takano H, Arakawa R, Nogami T, et al. Norepinephrine transporter occupancy by nortriptyline in patients with depression: A positron emission tomography study with (S, S)-[18F]FMeNER-D2. Int J Neuropsychopharmacol. 2014;17:553-60.PubMedCrossRef

86.

Douglas WW, Kanno T. The effect of amethocaine on acetylcholine-induced depolarization and catecholamine secretion in the adrenal chromaffin cell. Br J Pharmacol. 1967;30:612-9.

87.

Llinás R, Steinberg IZ, Walton K. Relationship between presynaptic calcium current and postsynaptic potential in squid giant synapse. Biophys J. 1981;33:323-51.PubMedCentralPubMedCrossRef

88.

Ackerknecht EH. History of the discovery of the vegetative (autonomic) nervous system. Med Hist. 1974;18:1-8.PubMedCentralPubMedCrossRef

89.

Chidsey CA, Braunwald E, Morrow AC. Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Am J Med. 1965;39:442-51.PubMedCrossRef

90.

Esler M, Lambert G, Brunner-La Rocca HP, Vaddadi G, Kaye D. Sympathetic nerve activity and neurotransmitter release in humans: Translation from pathophysiology into clinical practice. Acta Physiol Scand. 2003;177:275-84.PubMedCrossRef

91.

Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-Iodobenzylguanidine imaging and cardiac events in heart failure: Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55:2212-21.PubMedCrossRef

Title: Impact of medications on mIBG uptake, with specific attention to the heart: Comprehensive review of the literature
Authors: Arnold F. Jacobson, MD, PhD
Mark I. Travin, MD
Publication date: 01-10-2015
Publisher: Springer US
Published in: Journal of Nuclear Cardiology / Issue 5/2015
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-015-0170-z

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Impact of medications on mIBG uptake, with specific attention to the heart: Comprehensive review of the literature

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2015

Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: A substudy of the ASSUAGE and ASSUAGE-CKD trials

Impact of time-of-flight on qualitative and quantitative analyses of myocardial perfusion PET studies using 13N-ammonia

Debates: Introduction

Computed tomography: The optimal imaging method for differentiation of ischemic vs non-ischemic cardiomyopathy

A selection of recent, original research papers

Applied ethics for nuclear cardiology: Beginning a dialogue

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page